{"version":"1.2.0","chapters":[{"startTime":0,"endTime":33.222},{"startTime":33.222,"endTime":69.802,"title":"Introduction to Diabetic Kidney Disease"},{"startTime":69.802,"endTime":248.903,"title":"The Impact of Diabetes in Australia"},{"startTime":248.903,"endTime":495.979,"title":"Understanding Diabetic Nephropathy"},{"startTime":495.979,"endTime":545.034,"title":"Pathophysiology of Diabetic Nephropathy"},{"startTime":545.034,"endTime":747.671,"title":"Diagnosis of Chronic Kidney Disease"},{"startTime":747.671,"endTime":909.799,"title":"Management Objectives for Diabetic Kidney Disease"},{"startTime":909.799,"endTime":1107.895,"title":"The Four Pillars of Treatment"},{"startTime":1107.895,"endTime":1359.122,"title":"SGLT2 Inhibitors and Their Mechanism"},{"startTime":1359.122,"endTime":1652.011,"title":"Evidence from Landmark Studies"},{"startTime":1652.011,"endTime":1969.901,"title":"Non-Steroidal Mineralocorticoid Receptor Antagonists"},{"startTime":1969.901,"endTime":2322.444,"title":"GLP-1 Receptor Agonists: Benefits and Uses"},{"startTime":2322.444,"endTime":2454.605,"title":"Integrating Treatment Approaches"},{"startTime":2454.605,"endTime":2994.551,"title":"Case Discussions and Practical Applications"},{"startTime":2994.551,"endTime":3126.669,"title":"Risk Prediction Tools for Patients"}]}